Vatanidipine hydrochloride: a new long-lasting antihypertensive agent

Bibliography

• ABERNETHY DR, SCHWARTZ J: Calcium-antagonist drugs. N Engl. J. Med. (1999) 341:1447–1457.
   PubMed Web of Science ®Google Scholar
• SINGH V, CHRISTIANA J, FRISHMAN H: How to use calcium antagonists in hypertension: putting the JNC-VI guidelines into practice. Joint National Committee for prevention, detection, evaluation and treatment of high blood pressure. Drugs (1999) 58:579–587.
   Google Scholar
• ABERNETHY DR, GUTKOWSA J, WINTERBOTTOM LM:Effects of amlodipine, a long-acting dihydropyridine calcium antagonist in aging hypertension: pharma-cokinetics in relation to disposition. Chn. Pharmacol. Ther. (1990) 48:76–86.
   PubMed Web of Science ®Google Scholar
• HERBETTE LG, MASON PE, GAVIRAGHI G, TULENKO TN,MASON RP: The molecular basis for lacidipine's unique pharmacokinetics: optimal hydrophobicity results in membrane interactions that may facilitate the treatment of atherosclerosis. J. Cardiovasc. Pharmacol. (1994) 23 (Suppl. 5):S16–S–25.
   Google Scholar
• ASHIMORI A, ONO T, INOUE Y et al.: Novel1, 4-dihydropyridine calcium antagonists. II. Synthesis and antihypertensive activity of 344-(substituted amino)phenylalkyllester derivatives. Chem. Pharm. Bull. (1991) 39:91–99.
   Google Scholar
• KONDO N, ASHIMORI A, ONO S et al.: Chemical structure and physico-chemical properties of ((±)-244-(4-benzhydrylpiperazin-1-y1) phenyllethyl methyl 1,4-dihydro-2,6-dimethy1-4-(3-nitrophenyl) -pyridine-3,5-dicarboxylate dihydrochloride (AE0047). Iyakuhin Kenkyu (1997) 28:272–286.
   Google Scholar
• MASUMOTO K, TAKEYASU Q, OIZUMI K, KOBAYASHI T: Studies of novel 1,4-dihydropyridine Ca antagonist CS-905. I. Measurement of partition coefficient (log P) by high performance liquid chromatography (HPLC). Yakugaku Zasshi (1995) 115:213–220.
   Google Scholar
• OHKUBO M, HIRATA T, SOGAME Y, TANAKA M, OKANOK, TSUDA Y: Metabolic fate of a new dihydropyridine calcium antagonist, AE0047 (I): Absorption and excretion of AE0047, in rats and dogs. Xenobio. Metabol. Dispos. (1997) 12:178–191.
   Google Scholar
• OHKUBO M, HIRATA T, SOGAME Y, TANAKA M, OKANO K, TSUDA Y: Metabolic fate of a new dihydropyridine calcium antagonist, AE0047 (II): lymphatic absorp-tion and distribution of AE0047 in rats. Xenobio. Metabol. Dispos. (1997) 12:192–203.
   Google Scholar
• AZUMA J, HARADA H, KURIMOTO T, TOKUDA K, SETO Y: Phase I study of GJ-0956, Ca antagonist. J Clin. Ther. Med. (1997) 13:2121–2144.
   Google Scholar
• KAKU T, SUZUKI S, YANO K, DOT Y: Pharmacokineticstudy of GJ-0956 (watanidipine hydrochloride) in patients with essential hypertension. J Clin. Ther. Med. (1997) 13:2887–2905.
   Google Scholar
• NISHIKAWA M, GOHDA M, SHINYAMA H et al: Calcium channel blocking and vasodilating actions of the novel dihydropyridine derivative AE0047. Clin. Exp. Pharmacol. Physic)]. (1998) 25:347–354.
   PubMed Web of Science ®Google Scholar
• ••In vitro study indicating a slow-onset and a long-lastingcalcium channel blocking action of vatanidipine.
   Google Scholar
• YAMANAGA K, SHINYAMA H, AKIRA T et al: AE0047– mediated calcium channel blocking in vascular smooth muscles. Gen. Pharmacol. (1997) 29:337–343.
   Google Scholar
• •Study indicating calcium channel blocking action of vatanidipine in vascular smooth muscle.
   Google Scholar
• GOTOH Y, KUMADANI S, KAWAI T, IMAIZUMI Y, WATANABE M: Slow onset of and recovery from Ca blocking action of benidipine in rat aorta and portal vein. Jpn. j Pharmacol. (1989) 51:37–45.
   PubMedGoogle Scholar
• MORIMOTO S, MATSUMURA Y: Manidipine hydrochlo-ride [CV-4093 (2HC1)]. Cardiovasc. Drug Rev. (1991) 9:207–222.
   Google Scholar
• HOSONO M, FUJII S, HIRUMA T et al.: Inhibitory effectsof cilnidipine on vascular sympathetic neurotransmis-sion and subsequent vasoconstriction in spontane-ously hypertensive rats. Jpn. J. Pharmacol. (1995) 69:127–134.
   PubMedGoogle Scholar
• OKAMURA T, NISHIKAWA M, YOSHIDA K, TODA N: AE0047, a new dihydropyridine Ca2+ entry blocker, inhibits the responses to adrenergic nerve stimulation and substance P in dog mesenteric arteries. Eur. Pharmacol. (1992) 220:27–33.
   PubMed Web of Science ®Google Scholar
• •First study indicating the inhibitory action of vatanidipine on noradrenaline release from sympathetic nerve endings.
   Google Scholar
• YAMASAKI T, OHMAGARI M, TAMAI I, HAYASHI K, MATSUMURA Y: Inhibitory effects of AE0047, a new dihydropyridine Ca2+ channel blocker, on renal nerve stimulation-induced renal actions in anesthetized dogs. J. Pharmacol Exp. Ther. (2000) 293:1040–1047.
   PubMed Web of Science ®Google Scholar
• •Study indicating that vatanidipine inhibits renal nerve stimulation-induced antidiuresis and the noradrenaline overflow.
   Google Scholar
• HAYASHI K, GOHDA M, MATZNO S et al.: Possible mechanism of action of AE0047, a calcium antagonist, on triglyceride metabolism. J. Pharmacol Exp. Ther. (1997) 282:882–890.
   PubMed Web of Science ®Google Scholar
• ••In vivo and in vitro study indicating the beneficial effect ofvatanidipine on the lipid metabolism.
   Google Scholar
• HAYASHI K, IMADA T, YAMAUCHI T et al.: Possible mechanism for the anti-atherosclerotic action of the calcium channel blocker AE0047 in cholesterol-fed rabbits. Clin. Exp. Pharmacol Physic)]. (1998) 25:17–25.
   PubMed Web of Science ®Google Scholar
• ••Study indicating that in cholesterol-fed rabbits, vatanidipineexhibits an anti-atherosclerotic action, which is probably attributable to the inhibitory action of the agent on LDL-oxidation.
   Google Scholar
• KOIBUCHI Y, SAKAI S, MIURA S, ONO T, SHIBAYAMA F, OHTSUKA M: Suppression of atherogenesis in cholesterol-fed rabbits treated with nilvadipine, a new vasoselective calcium entry blocker. Atherosclerosis (1989) 79:147–155.
   PubMed Web of Science ®Google Scholar
• HASHIMOTO K, TAIRA N, CHIBA S et al.: Cardiohemody-namic effects of BAY a 1040 in the dog. Arzneimittel forschung (1972) 22:15–21.
   PubMed Web of Science ®Google Scholar
• BRUUN NE, IBSEN H, NIELSEN F, NIELSEN MD, MOELBAKAG, HARTLING 01: lack of effect of nifedipine on counterreg-ulatory mechanisms in essential hyperten-sion. Hypertension (1986) 8:655–661.
   PubMedGoogle Scholar
• OHTSUKA K, TSUKIYAMA H, ONO Y, ISHII Y, MIYAZAKIN, SUMIDA Y: Hemodynamic effect of the novel dihydropyridine calcium antagonist GJ-0956 (watanidipine hydrochloride) in essential hyperten-sion. Rinsho Iyaku (1997) 13:2907–2950.
   Google Scholar
• TAKEDA T, IIMURA 0, ABE K et al.: Clinical evaluation ofGJ-0965 on essential hypertension - A double-blind comparative study with nitrendipine. Rinsho Iyaku (1999) 15:1385–1428.
   Google Scholar
• •Clinical study indicating that in spite of a potent hypotensive effect, the incidence of adverse effects after vatanidipine treatment is lower than that after nitrendipine treatment.
   Google Scholar
• KIDO H, NISHIKAWA M, HAYASHI K et al.: An tihyp er ten - sive effects of a novel calcium antagonist, AE0047, in various hypertensive models. Folia Pharmacol. Jpn. (1997) 109:279–289.
   PubMedGoogle Scholar
• ••First study indicating the antihypertensive action ofvatanidipine in various hypertensive animal models.
   Google Scholar
• KIDO H, NISHIKAWA M, HAYASHI K et al.: An tihyp er ten - sive effects of a long term treatment with AE0047, a novel long-lasting calcium antagonist, in hypertensive models of rats and dogs. Folia Pharmacol Jpn. (1997) 109:291–301.
   PubMedGoogle Scholar
• ••First study indicating the antihypertensive action oflong-term treatment with vatanidipine in hypertensive animal models.
   Google Scholar
• NISHIKAWA M, OKAMURA Y, TODO N: Effect of the novel calcium antagonist AE0047 on responses of isolated dog blood vessels to vasoconstricting agents and to nerve stimulation. Folia Pharmacol. Jpn. (1995) 106:19–29.
   PubMedGoogle Scholar
• KIDO H, UCHIDA Y, NAKAMURA F, SUGIMOTO T: Angiographic studies on the effects of a novel calcium antagonist AE0047 on cerebral arteries in dogs, with special reference to the preventive effects of AE0047 on cerebral vasoconstriction induced by endothelin. Folia Pharmacol. Jpn. (1990) 95:177–184.
   PubMed Web of Science ®Google Scholar
• BAETHMANN A, JANSEN M: Possible role of calcium entry blockers in brain protection. Eur. Neurol (1986) 25 (Suppl. 1) :102–114.
   Google Scholar
• SIESJO BK, BENGTSSON F: Calcium fluxes, calcium antagonists and calcium-related pathology in brain ischemia, hypoglycemia and spreading depression: A unifying hypothesis. J. Cereb. Blood Flow Metab. (1989) 9:127–140.
   PubMed Web of Science ®Google Scholar
• LIPTON SA: Calcium channel antagonists in theprevention of neurotoxicity. Adv. Pharmacol. (1991) 22:271–297.
   PubMedGoogle Scholar
• MEYER FB, SUNDT T, YANAGIHARA T, ANDERSON RE:Focal cerebral ischemia: pathophysiologic mechanisms and rationale for future avenues of treatment. Mayo Clinic Proc. (1987) 62:35–55.
   PubMed Web of Science ®Google Scholar
• SIESJO BK: Pathophysiology and treatment of focalcerebral ischemia, Part II: mechanisms of damage and treatment. J Neurosurg. (1992) 77:337–354.
   PubMed Web of Science ®Google Scholar
• HARRIS RJ, BRANSTON NM, SYMON L, BAYHAN M, WATSON A: The effects of a calcium antagonist, nimodipine, upon physiological responses of the cerebral vasculature and its possible influence upon focal cerebral ischemia. Stroke (1982) 13:759–766.
   PubMed Web of Science ®Google Scholar
• VORSTRUP S, ANDERSON A, BLEGVAD N, PAULSON OB:Calcium antagonist (PY 108-068) treatment may further decrease flow in ischemic areas in acute stroke. J. Cereb. Blood Flow Metab. (1986) 6:222–229.
   PubMed Web of Science ®Google Scholar
• SHINYAMA H, HAYASHI K, KAWAMURA T, NAKAMURA N,KAGITANI Y: Effects of AE0047 on cerebral ischaemia and oedema after middle cerebral artery occlusion in cats. Clin. Exp. Pharmacol. Physiol. (1997) 24:824–830.
   PubMed Web of Science ®Google Scholar
• YAMANAGA K, OHTAKI Y, UCHIDA T, WATANABE M: Effect of a novel calcium antagonist AE0047 on several models of cerebral ischemia. Drug Development Res. (1992) 26:173–181.
   Web of Science ®Google Scholar
• SHINYAMA H, NAGAI H, KAWAMURA T et al.: Protective effects of AE0047, a novel calcium antagonist, on incidence of stroke and hemodynamic disturbances in stroke-prone spontaneously hypertensive rats. J Pharmacol. Exp. Ther. (1995) 272:911–919.
   PubMed Web of Science ®Google Scholar
• ••First study indicating that vatanidipine protects againstcerebrovascular lesions, mostly through a mechanism independent of its hypotensive effect.
   Google Scholar
• LOUTZENHISER R, EPSTEIN M: Effects of calcium antagonists on renal hemodynamics. Am. J. Physiol (1985) 249:F619–F629.
   PubMed Web of Science ®Google Scholar
• ZANCHETTI A, LEONETTI G: Natriuretic effect of calcium antagonists. J. Cardiovasc. Pharmacol (1985) 7 (Suppl. 4):S33–S37.
   Google Scholar
• BROWN B, CHURCHILL PC: Renal effects of methoxy-verapamil in anesthetized rats. J. Pharmacol. Exp. Ther. (1983) 225:372–377.
   PubMedGoogle Scholar
• JOHNS EJ: The influence of diltiazem and nifedipine on renal function in the rat. Br. J Pharmacol. (1985) 84:707–713.
   PubMed Web of Science ®Google Scholar
• IMAGAWA J, KUROSAWA H, SATOH S: Effects of nifedipine on renin release and renal function in anesthetized dogs. J. Cardiovasc. Pharmacol. (1986) 8:636–640.
   PubMed Web of Science ®Google Scholar
• KAGEYAMA M, MATSUMURA Y, SASAKI Y et al.: Inhibi-tory effect of nisoldipine on angiotensin II-induced renal actions in anesthetized dogs. J Cardiovasc. Pharmacol. (1986) 14:96–102.
   Google Scholar
• DIBONA GF, SAWIN LL: Renal tubular site of action offelodipine. j Pharmacol. Exp. Ther. (1984) 228:420–424.
   PubMed Web of Science ®Google Scholar
• HABERLE DA, KAWATA T, DAVIS JM: The site of action ofnitrendipine in the rat kidney. J. Cardiovasc. Pharmacol (1987) 9 (Suppl. 1) :517–523.
   Google Scholar
• HAYASHI K, UCHIDA T, KIDO H, SHINYAMA H, WATANABE M: Effects of AE0047 on renal haemody-namics and function in anaesthetized dogs. Clin. Exp. Pharmacol. Physic)]. (1993) 20:103–111.
   PubMed Web of Science ®Google Scholar
• •Study indicating the diuretic and natriuretic effects of vatanidipine administered intrarenally in dogs.
   Google Scholar
• HAYASHI K, KIDO H, KUBO Y, SHINYAMA H, NAKAMURAN, KAGITANI Y: Effects of the calcium channel blocker AE0047 on renal function in conscious spontaneously hypertensive rats: Focus on renal proximal tubules. Drug Development Res. (1997) 41:91–98.
   Web of Science ®Google Scholar
• RAU L: Role of hypertension in progressive glomerularinjury in glomerulonephritis. Hypertension (1986) 8 (Suppl. I):130–133.
   Google Scholar
• STIER CT, BENTER IF, AHMAD S: Enalapril preventsstroke and kidney dysfunction in salt-loaded stroke-prone spontaneously hypertensive rats. Hypertension (1989) 13:115–121.
   PubMed Web of Science ®Google Scholar
• WADA T, KANAGAWA R, ISHIMURA Y, INADA Y, NISHIKAWA K: Role of angiotensin II in cerebrovas-cular and renal damage in deoxycorticosterone acetate-salt hypertensive rats. J Hypertens. (1995) 13:113–122.
   PubMed Web of Science ®Google Scholar
• SUZUKI M, YAMADA K, NABATA H, TACHIBANA M: bongterm effects of amlodipine on organ damage, stroke and life span in stroke-prone spontaneously hypertensive rats. Eur.J. Pharmacol (1993) 228:269–274.
   PubMed Web of Science ®Google Scholar
• HAYASHI K, KOYAMA M, KIDO H et al.: Preventive and therapeutic effects of AE0047 on renal injury in stroke-prone spontaneously hypertensive rats. Clin. Exp. Pharmacol. Physic)]. (1997) 24:831–840.
   PubMed Web of Science ®Google Scholar
• ••First study indicating the renoprotective effect ofvatanidipine in stroke-prone spontaneously hypertensive rats.
   Google Scholar
• FLEMING JT, PAREKH N, STEINHAUSEN M: Calcium antagonists preferentially dilate preglomerular vessels of hydronephrotic kidney. Am J. Physiol. (1987) 253:F1157–F1163.
   PubMed Web of Science ®Google Scholar
• TOJO A, KIMURA K, MATSUOKA H, SUGIMOTO T: Effectsof manidipine on the renal microcirculation in spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. (1992) 20:895–899.
   PubMed Web of Science ®Google Scholar
• HAYASHI K, NAGAHAMA T, OKA K, EPSTEIN M, SARUTAT: Disparate effects of calcium antagonists on renal microcirculation. Hypertens. Res. (1996) 19:31–36.
   PubMedGoogle Scholar
• HAYASHI K, EGI Y, KUBO Y, KIDO H, NAKAMURA N, KAGITANI Y: A calcium channel blocker, AE0047 dilates the efferent arterioles in angiotensin II-infused anesthetized dogs. Jpn. Pharmacol. Ther. (1997) 25:1339–1345.
   Google Scholar
• TAKEDA T, IIMURA 0, ABE K et al.: Pilot study onefficacy and safety of GJ-0956 in patients with essential hypertension. Rinsho Iyaku (1997) 13:2183–2198.
   Google Scholar
• NAKASHIMA M, UEMATSU T: Pharmacokinetics and antihypertensive effect of GJ-0956 in patients with essential hypertension. Rinsho Iyaku (1997) 13:2169–2182.
   Google Scholar
• •Clinical study indicating long-lasting antihypertensive action of vatanidipine in patients with essential hypertension.
   Google Scholar
• TAKEDA T, IIMURA 0, ABE K et al.: Effect of GJ-0956 on diurnal blood pressure variation in patients with essential hypertension. Rinsho Iyaku (1997) 13:2199–2211.
   Google Scholar
• TAKEDA T, IIMURA 0, ABE K et al.: Efficacy and safety of GJ-0956 monotherapy in patients with essential hypertension. A late Phase II study for evaluation of optimum dose. Rinsho Iyaku (1997) 13:2213–2236.
   Google Scholar
• TAKEDA T, IIMURA 0, ABE K et al: Efficacy and safety of GJ-0956 in combination with diuretic orB-blocker in patients with essential hypertension. A late Phase II study for evaluation of optimum dose. Rinsho Iyaku (1997) 13:2237–2264.
   Google Scholar
• TAKEDA T, IIMURA 0, ABE K et al.: Efficacy and safety ofGJ-0956 in long-term administration of patients with essential hypertension. Rinsho Iyaku (1997) 15:2373–2407.
   Google Scholar
• UEDA Y, MORI H, SAKAMOTO T, AOI W: Effect of GJ-0956 on renal function in subjects with essential hypertension and/or diabetic penopathies. Rinsho Iyaku (1997) 13:2299–2315.
   Google Scholar
• YAMAKADO M: Effect of GJ-0956 on serum lipid and carbohydrate metabolism in patients with essential hypertension. Rinsho Iyaku (1997) 13:2317–2329.
   Google Scholar
• KOSHIBA H, IKEDA Y, FUKUNAGA Y et al.: Single dose toxicity study of watanidipine hydrochloride in mice and rats. Jpn. Pharmacol. Ther. (1997) 25 (Suppl. 3):5465–S482.
   Google Scholar
• KOSHIBA H, IRIE H, KIMURA K, KASHIHARA J,KAWABATA Y, ABE S: 13-week oral repeated dose toxicity study of watanidipine hydrochloride in rats. Jpn. Pharmacol. Ther. (1997) 25 (Suppl. 3):S505–5533.
   Google Scholar
• MATSUDA A, KARAYAMA Y, KOMATSU H, YONEYAMA S,KOSHIBA H, ABE S: 12-month oral repeated dose toxicity study of watanidipine hydrochloride in rat. Jpn. Pharmacol. Ther. (1997) 25 (Suppl. 3):5577–5593.
   Google Scholar
• IKEDA Y, FUKUNAGA Y, KIMURA K et al.: 13-week oralrepeated dose toxicity study of watanidipine hydrochloride in dogs. Jpn. Pharmacol. Ther. (1997) 25 (Suppl. 3):S535–S574.
   Google Scholar
• SAWADA T, NAKAMURA M, KOMATSU H et al.: 12-month oral repeated dose toxicity study of watanidipine hydrochloride in dogs. Jpn. Pharmacol. Ther. (1997) 25 (Suppl. 3):S595–S624.
   Google Scholar
• KOMAI Y, KATANO T, HATTORI M et al.: Reproductive and developmental toxicity study of watanidipine hydrochloride (1) Fertility study in rats by oral administration. Jpn. Pharmacol. Ther. (1997) 25 (Suppl. 3):S625–S634.
   Google Scholar
• HATTORI M, OGURA H, ISOWA K et al.: Reproductiveand developmental toxicity study of watanidipine hydrochloride (2) Teratogenicity study in rats by oral administration. Jpn. Pharmacol. Ther. (1997) 25 (Suppl. 3):S635–S647.
   Google Scholar
• HATTORI M, OGURA H, KATANO T et al: Reproductiveand developmental toxicity study of watanidipine hydrochloride (3) Pen- and post natal study in rats by oral administration. Jpn. Pharmacol. Ther. (1997) 25 (Suppl. 3):S649–S659.
   Google Scholar
• KOMAI Y, KATANO T, HATTORI M et al.: Reproductiveand developmental toxicity study of watanidipine hydrochloride (4) Teratogenicity study in rabbits by oral administration. Jpn. Pharmacol. Ther. (1997) 25 (Suppl. 3):S661–S668.
   Google Scholar
• UMEMURA A, KOSHIBA H, ABE S: Antigenicity study ofwatanidipine hydrochloride in guinea-pig and mouse. Jpn. Pharmacol. Ther. (1997) 25 (Suppl. 3):S669–S674.
   Google Scholar
• ANDO N, KOSHIBA H, ABE S: Mutagenicity studies ofwatanidipine hydrochloride in bacteria reverse mutation test, in vitro chromosomal aberration test and mouse bone-marrow micronucleus test. Jpn. Pharmacol. Ther. (1997) 25 (Suppl. 3):S675–S684.
   Google Scholar
• ISHIDA S, IKEYA M, FUKUZUMI H et al: Carcinogenicity study of watanidipine hydrochloride in mice by [dietary administration]. Jpn. Pharmacol Ther. (1997) 25 (Suppl. 3):S685–S704.
   Google Scholar
• ISHIDA S, IKEYA M, FUKUZUMI H et al: Carcinogenicity study of watanidipine hydrochloride in rats by dietary administration. Jpn. Pharmacol. Ther. (1997) 25 (Suppl. 3):S705–S728.
   Google Scholar